Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$92.13MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Meeker
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 414
- Beta
- 2.13
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 14.68
Financials
Revenue
$92.13M+263122.9%Net Income
$-41.37MEBITDA
$-36.26MFree Cash Flow
$-3.56MEPS (diluted)
$-0.61Shares Outstanding (diluted)
69.05M+312.7%Operating Expenses
$119.23MCash & Debt
$320.94MReturn of Capital
$1.46MRevenue by Segment (annual)
$189.76MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $189.76M | $-196.54M | $-3.11 |
| 2024 | $130.13M | $-260.60M | $-4.34 |
| 2023 | $77.43M | $-184.68M | $-3.20 |
| 2022 | $23.64M | $-181.12M | $-3.51 |
| 2021 | $3.15M | $-69.61M | $-1.37 |
| 2020 | $0.00 | $-130.73M | $-2.96 |
| 2019 | $0.00 | $-134.62M | $-3.70 |
| 2018 | $0.00 | $-74.06M | $-2.39 |
| 2017 | $0.00 | $-33.71M | $-1.26 |
| 2016 | $0.00 | $-25.87M | $-1.55 |
| 2015 | $0.00 | $-11.07M | $-1.09 |
| 2014 | $0.00 | $-6.49M | $-0.64 |
| 2013 | $0.00 | $-21.43M | $-0.43 |
| 2012 | $0.00 | $-18.13M | $-0.36 |
Valuation
RYTMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (22)
- Newsglobenewswire.com·6d ago·Negative
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026 – Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –
View source ↗ - News (RSS)seekingalpha·12d ago·Positive
Rhythm Pharmaceuticals: Bull Case Intact, But The Market Is Pricing In A Lot
View source ↗ - Newsseekingalpha.com·12d ago·Neutral
…s Pricing In A Lot Rhythm Pharmaceuticals maintains strong commercial momentum, with IMCIVREE sales up 79.5% YoY and a broadening prescriber base in the acquired HO. RYTM's valuation is elevated at 27.4x trailing sales, reflecting high expectations for sustained growth and successful international launches. Takeover speculation, including a reported $124/share AstraZeneca bid, is supporting the share price but inflates the takeover premium over fundamentals.
View source ↗ - News (RSS)zerohedge·17d ago·Negative
Nintendo Switch 2 Sales Plunge Amid Memory Crisis; Bernstein Calls It "Not A Good Result" Nintendo Switch 2 Sales Plunge Amid Memory Crisis; Bernstein Calls It "Not A Good Result" Nintendo Switch 2 sales came in materially below Wall Street expectations. Second quarter earnings showed a 41% decline in sales as price increases, shortages, and the memory crisis weighed on demandThe Kyoto-based gaming company sold 2.67 million consoles in the three months ended Sept. 30, down from 3.82 million in t
View source ↗ - News (Marketaux)seekingalpha.com·17d ago·Neutral
Rhythm Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:RYTM) 2026-11-05 Rhythm Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:RYTM) 2026-11-05
View source ↗ - News (RSS)seekingalpha·17d ago·Neutral
Rhythm Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - News (RSS)wsj·18d ago·Neutral
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals Rhythm specializes in treatments for metabolic conditions and severe obesity.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
Rhythm Pharmaceuticals Q3 Earnings Call Highlights Rhythm Pharmaceuticals NASDAQ: RYTM reported third-quarter global net product sales of $92.1 million, up 29% sequentially, as the company cited a strong early U.S. launch for IMCIVREE in acquired hypothalamic obesity, or acquired HO. The company also outlined plans to advance bivamelagon into Phase III studies for acquired HO and Prader-Willi syndrome, while expanding its international commercial footprint.
View source ↗ - Newszacks.com·19d ago·Neutral
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.82 per share a year ago.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update -- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, an increase of 29% from the prior quarter -- -- Commercial launch of IMCIVREE in Japan for patients with acquired HO underway -- -- Bivamelagon …
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement -- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payments totaling $350 million over four years --
View source ↗ - News (RSS)zerohedge·22d ago·Positive
The Pendulum Of History The Pendulum Of History Authored by Charles Hugh Smith via Of Two Minds,This is Essay #8 in the series Truth Be Told.A great many phenomena in both Nature and human history follow cyclical patterns, while others form waves. Author David Hackett Fischer (The Great Wave: Price Revolutions and the Rhythm of History) described the difference between cycles and waves:"Cyclical rhythms are fixed and regular. Their periods are highly predictable. Great waves are more variable an
View source ↗ - Newszacks.com·26d ago·Neutral
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
…ceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporat…
View source ↗ - News (RSS)investing·39d ago·Neutral
Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
View source ↗ - Newszacks.com·40d ago·Positive
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know Rhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·73d ago·Neutral
…ts across multiple cardiometabolic risk indices with setmelanotide in acquired HO -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced Rhythm and its collaborators will present three posters and three oral presentations relating to the company's work in rare melanocortin-4 receptor (MC4R) pathway diseases…
View source ↗ - News (Marketaux)finance.yahoo.com·91d ago·Positive
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can A little-known biotech, Rhythm [+319 characters]
View source ↗ - Newsglobenewswire.com·97d ago·Neutral
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17.
View source ↗ - Newsbenzinga.com·102d ago·Neutral
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday? Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shares are trading higher on Wednesday.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-2.84 per share
Typical surprise +3.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-0.61 vs $-0.71beat
- Tue, Aug 4$-0.73 vs $-0.81beat
- Tue, May 5$-0.83 vs $-0.86beat
- Thu, Feb 26$-0.73 vs $-0.79beat
- Tue, Nov 4$-0.82 vs $-0.72miss
- Tue, Aug 5$-0.75 vs $-0.66miss
Estimates and results for RYTM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RYTM officers and directors.
- Bought
- —
- Sold
- $40.0m
0 trades
27 trades
- Shulman Josephsold
- Jean Christophesold
- Jean Christophesold
- Jean Christophesold
- Meeker David Psold
- Meeker David Psold
- Meeker David Psold
- Meeker David Psold
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RYTM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
